{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:30:23Z","timestamp":1793651423891,"version":"4.5.1"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>The success of solid organ transplantation (SOT) and the use of immunosuppressive agents offer hope to patients with end-stage diseases. However, the impact of post-transplant diabetes mellitus (PTDM) on SOT patients has become increasingly evident. In our study, we utilized the Scientific Registry of Transplant Recipients (SRTR) database to investigate the association between PTDM and patient survival in various types of organ transplantations, including liver, kidney, intestinal, heart, lung, and combined heart-lung transplantations (all <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). Our findings revealed a negative effect of PTDM on the survival of these patients. Furthermore, we examined the effects of both generic and innovator immunosuppressive agents on the development of PTDM and the overall survival of different SOT populations. Interestingly, the results were inconsistent, indicating that the impact of these agents may vary depending on the specific type of transplantation and patient population. Overall, our study provides a comprehensive and systematic assessment of the effects of different immunosuppressive agents on prognosis, as well as the impact of PTDM on the survival of patients undergoing various types of SOT. These findings emphasize the need for further research and highlight the importance of optimizing immunosuppressive regimens and managing PTDM in SOT patients to improve their long-term outcomes.<\/jats:p>","DOI":"10.1097\/js9.0000000000001135","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T08:00:33Z","timestamp":1707811233000},"page":"2007-2024","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Impact of varied immunosuppressive agents and post-transplant diabetes mellitus on prognosis among diverse transplant recipients (experimental studies)"],"prefix":"10.1097","volume":"110","author":[{"given":"Yuan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Liver Transplantation, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Global Health, Chinese Center for Tropical Diseases Research, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qining","family":"He","sequence":"additional","affiliation":[{"name":"Department of Liver Transplantation, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Huadong Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhen","family":"Wen","sequence":"additional","affiliation":[{"name":"Organ Transplantation Institute of Xiamen University, Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihao","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifu","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Kidney Transplantation, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London, South Kensington Campus, London SW72AZ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Kidney Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangrang","family":"Wang","sequence":"additional","affiliation":[{"name":"Huadong Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4]]},"reference":[{"key":"R1-20250824","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1210\/er.2015-1084","article-title":"Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes","volume":"37","author":"Shivaswamy","year":"2016","journal-title":"Endocr Rev"},{"key":"R2-20250824","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41574-018-0137-7","article-title":"Post-transplant diabetes mellitus in patients with solid organ transplants","volume":"15","author":"Jenssen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/s41591-022-01758-7","article-title":"Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes","volume":"28","author":"Shaked","year":"2022","journal-title":"Nat Med"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transplant"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-8587(15)00387-3","article-title":"Post-transplantation diabetes-state of the art","volume":"4","author":"Sharif","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R6-20250824","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/TP.0000000000003867","article-title":"Management of diabetes in candidates for liver transplantation and in transplant recipients","volume":"106","author":"Brodosi","year":"2022","journal-title":"Transplantation"},{"key":"R7-20250824","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/tri.12757","article-title":"Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria","volume":"29","author":"Eide","year":"2016","journal-title":"Transpl Int"},{"key":"R8-20250824","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.metabol.2016.07.011","article-title":"Risk assessment and management of post-transplant diabetes mellitus","volume":"65","author":"Han","year":"2016","journal-title":"Metabolism"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1093\/cid\/ciaa1189","article-title":"Immunosuppressive agents and infectious risk in transplantation: managing the \u201cNet State of Immunosuppression","volume":"73","author":"Roberts","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/08923973.2021.1966033","article-title":"Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs","volume":"43","author":"Parlakpinar","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"R11-20250824","first-page":"813","article-title":"Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation","volume":"42","author":"Nguyen","year":"2019","journal-title":"Drug Safety"},{"key":"R12-20250824","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s40265-013-0136-x","article-title":"Immunosuppression and allograft rejection following lung transplantation: evidence to date","volume":"73","author":"Snell","year":"2013","journal-title":"Drugs"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14712598.2017.1283400","article-title":"Use of polyclonal\/monoclonal antibody therapies in transplantation","volume":"17","author":"Yeung","year":"2017","journal-title":"Expert Opinion Biol Ther"},{"key":"R15-20250824","first-page":"Cd004759","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"1","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(71)92046-0","article-title":"Cyclophosphamide and human organ transplantation","volume":"2","author":"Starzl","year":"1971","journal-title":"Lancet"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1053-2498(99)00072-8","article-title":"Cyclophosphamide rescue therapy for chronic rejection after lung transplantation","volume":"18","author":"Verleden","year":"1999","journal-title":"J Heart Lung Transplant"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/endrev\/bnaa030","article-title":"Metabolic consequences of solid organ transplantation","volume":"42","author":"Bhat","year":"2021","journal-title":"Endocr Rev"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"101752","DOI":"10.1016\/j.eclinm.2022.101752","article-title":"Genotype-guided model significantly improves accuracy of tacrolimus initial dosing after liver transplantation","volume":"55","author":"Shi","year":"2023","journal-title":"EClinicalMed"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.transproceed.2022.01.030","article-title":"Risk factors for new-onset diabetes mellitus after heart transplantation: a nomogram approach","volume":"54","author":"Wang","year":"2022","journal-title":"Transplant Proc"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jinf.2011.12.005","article-title":"Multidrug-resistant gram-negative bacterial infections after liver transplantation - spectrum and risk factors","volume":"64","author":"Zhong","year":"2012","journal-title":"J Infect"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.ccell.2021.08.005","article-title":"Activating a collaborative innate-adaptive immune response to control metastasis","volume":"39","author":"Sun","year":"2021","journal-title":"Cancer Cell"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cellular Endocrinol"},{"key":"R24-20250824","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1111\/tri.14142","article-title":"Steroid withdrawal after heart transplantation in adults","volume":"34","author":"Heegaard","year":"2021","journal-title":"Transpl Int"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13300-020-00790-5","article-title":"Post-transplantation diabetes mellitus","volume":"11","author":"Ahmed","year":"2020","journal-title":"Diab Ther"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1399-0012.2007.00683.x","article-title":"Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes","volume":"21","author":"Humar","year":"2007","journal-title":"Clin Transplant"},{"key":"R28-20250824","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"R29-20250824","doi-asserted-by":"crossref","first-page":"e149934","DOI":"10.1172\/JCI149934","article-title":"Calcineurin inhibitors target Lck activation in graft-versus-host disease","volume":"131","author":"Carter","year":"2021","journal-title":"J Clin Invest"},{"key":"R30-20250824","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature05097","article-title":"Calcineurin\/NFAT signalling regulates pancreatic beta-cell growth and function","volume":"443","author":"Heit","year":"2006","journal-title":"Nature"},{"key":"R31-20250824","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ajt.15665","article-title":"The tacrolimus-induced glucose homeostasis imbalance in terms of the liver: From bench to bedside","volume":"20","author":"Ling","year":"2020","journal-title":"Am J Transplant"},{"key":"R32-20250824","first-page":"Cd003961","article-title":"Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients","author":"Webster","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R33-20250824","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/tri.12798","article-title":"A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation","volume":"29","author":"Shuker","year":"2016","journal-title":"Transpl Int"},{"key":"R34-20250824","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R35-20250824","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.healun.2022.07.011","article-title":"Post-transplant diabetes mellitus following heart transplantation","volume":"41","author":"Newman","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"R36-20250824","doi-asserted-by":"crossref","first-page":"e0226873","DOI":"10.1371\/journal.pone.0226873","article-title":"Comparison of post-transplantation diabetes mellitus incidence and risk factors between kidney and liver transplantation patients","volume":"15","author":"Munshi","year":"2020","journal-title":"PLoS One"},{"key":"R37-20250824","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/358070a0","article-title":"Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase","volume":"358","author":"Kuo","year":"1992","journal-title":"Nature"},{"key":"R38-20250824","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1681\/ASN.2010040351","article-title":"The evolving role of mTOR inhibition in transplantation tolerance","volume":"22","author":"McMahon","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R39-20250824","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00003495-200767030-00004","article-title":"Use of sirolimus in solid organ transplantation","volume":"67","author":"Augustine","year":"2007","journal-title":"Drugs"},{"key":"R40-20250824","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opinion Drug Safety"},{"issue":"2S suppl 1","key":"R41-20250824","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/TP.0000000000001690","article-title":"mTOR inhibition and clinical transplantation: liver","volume":"102","author":"Nashan","year":"2018","journal-title":"Transplantation"},{"key":"R42-20250824","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.trre.2015.12.003","article-title":"Use of everolimus in liver transplantation: the French experience","volume":"30","author":"Dumortier","year":"2016","journal-title":"Transplant Rev (Orlando)"},{"key":"R43-20250824","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17512433.2021.1851596","article-title":"Pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression","volume":"14","author":"Chevallier","year":"2021","journal-title":"Exp Rev Clin Pharmacol"},{"key":"R44-20250824","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"2 Suppl","key":"R45-20250824","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"key":"R46-20250824","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","article-title":"Mechanism of action of mycophenolate mofetil","volume":"17","author":"Ransom","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R47-20250824","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant"},{"key":"R48-20250824","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/j.1600-6143.2009.02705.x","article-title":"Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil","volume":"9","author":"Germani","year":"2009","journal-title":"Am J Transplant"},{"key":"R49-20250824","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199808270-00016","article-title":"A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators","volume":"66","author":"Kobashigawa","year":"1998","journal-title":"Transplantation"},{"key":"R50-20250824","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00467-017-3735-z","article-title":"Generic immunosuppressants","volume":"33","author":"Medeiros","year":"2018","journal-title":"Pediatric Nephrol (Berlin, Germany)"},{"key":"R51-20250824","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1574884712666170809124728","article-title":"Monoclonal antibodies: a review","volume":"13","author":"Singh","year":"2018","journal-title":"Curr Clin Pharmacol"},{"key":"R52-20250824","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00003495-199651050-00010","article-title":"Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection","volume":"51","author":"Wilde","year":"1996","journal-title":"Drugs"},{"key":"R53-20250824","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/ajt.13739","article-title":"The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients","volume":"16","author":"Furuya","year":"2016","journal-title":"Am J Transplant"},{"key":"R54-20250824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20620","article-title":"Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model","volume":"20","author":"Jones-Hughes","year":"2016","journal-title":"Health Technol Assessm"},{"key":"R55-20250824","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.transproceed.2007.06.021","article-title":"Do anti-CD25 monoclonal antibodies potentiate posttransplant diabetes mellitus?","volume":"39","author":"Bay\u00e9s","year":"2007","journal-title":"Transplant Proc"},{"key":"R56-20250824","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.2174\/1381612826666200506094539","article-title":"ABO-incompatible liver transplantation: state of art and future perspectives","volume":"26","author":"Cheng","year":"2020","journal-title":"Curr Pharmaceut Design"},{"key":"R57-20250824","doi-asserted-by":"crossref","first-page":"e923502","DOI":"10.12659\/AOT.923502","article-title":"ABO-incompatible living donor liver transplantation with reduced rituximab dose: a retrospective analysis of 65 patients - can we fast-track liver transplant surgery and improve long-term survival?","volume":"25","author":"Hsu","year":"2020","journal-title":"Ann Transplantat"},{"key":"R58-20250824","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.transproceed.2020.01.139","article-title":"Early steroid withdrawal protocol with basiliximab and rituximab in abo-incompatible kidney transplant recipients","volume":"52","author":"Tojimbara","year":"2020","journal-title":"Transplant Proc"},{"key":"R59-20250824","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/TP.0000000000001849","article-title":"Anti-CD20 blocker rituximab in kidney transplantation","volume":"102","author":"Sood","year":"2018","journal-title":"Transplantation"},{"key":"R60-20250824","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00007890-200204150-00015","article-title":"Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients","volume":"73","author":"Ciancio","year":"2002","journal-title":"Transplantation"},{"key":"R61-20250824","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/01.TP.0000154915.20524.0A","article-title":"Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation","volume":"79","author":"Rostaing","year":"2005","journal-title":"Transplantation"},{"key":"R62-20250824","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/01.tp.0000442505.10490.20","article-title":"Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants","volume":"97","author":"Popat","year":"2014","journal-title":"Transplantation"},{"key":"R63-20250824","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1097\/00007890-200005150-00026","article-title":"Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines","volume":"69","author":"Zuckermann","year":"2000","journal-title":"Transplantation"},{"key":"R64-20250824","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ctr.12469","article-title":"Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents","volume":"29","author":"Whitson","year":"2015","journal-title":"Clin Transplant"},{"key":"R65-20250824","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ajh.23995","article-title":"An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide","volume":"90","author":"Shabbir-Moosajee","year":"2015","journal-title":"Am J Hematol"},{"key":"R66-20250824","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3389\/fimmu.2019.03138","article-title":"Cyclophosphamide-induced tolerance in allogeneic transplantation: from basic studies to clinical application","volume":"10","author":"Kato","year":"2019","journal-title":"Front Immunol"},{"key":"R67-20250824","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"key":"R68-20250824","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"R69-20250824","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1053-2498(00)00211-4","article-title":"Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation","volume":"20","author":"Grauhan","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"R70-20250824","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/TP.0b013e3181b9ca69","article-title":"Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog","volume":"88","author":"Ushitora","year":"2009","journal-title":"Transplantation"},{"key":"R71-20250824","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1399-0012.2009.01070.x","article-title":"FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study","volume":"23","author":"Tedesco-Silva","year":"2009","journal-title":"Clin Transplant"},{"issue":"suppl 17","key":"R72-20250824","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1399-0012.2006.00596.x","article-title":"FTY720 (fingolimod) in renal transplantation","volume":"20","author":"Budde","year":"2006","journal-title":"Clin Transplant"},{"key":"R73-20250824","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"R74-20250824","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T19:01:53Z","timestamp":1756062113000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":74,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001135","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"2023-09-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}